MaaT signed a licensing, distribution, and commercial supply agreement with Clinigen in Europe for Xervyteg (MaaT013, microbiome therapy, enema formulation) in aGvHD for a € 10.5m upfront, € 18m in milestones, and mid-thirties flat royalty on sales. We believe this deal serves as validation of MaaT013's potential, and see the partnership as a de-risking event for MaaT013's commercialisation in Europe, given Clinigen's experience commercialising in haemato-oncology, with 3 products currently on t...
Since the last publication of our Dynamic Top Pick List on 5 June 2025, our selection has seen again a nice outperformance versus the reverence indices (AEX, Bel20 and Eurostoxx50) of on average 3.3%. Our July update brings 3 adjustments to the list : Since being added to the list in December 2024, Fagron's share price has surged +/-22%, driven by strong Q1 2025 results and robust growth across all regions. Fagron reaffirmed its FY25 guidance and unveiled its “Compounding for Growth” strategy, ...
After contact with IR, we learned that 2Q25 has its challenges, mostly in line with 1Q. Idle time due to the ending of large contracts and ramping up of new ones was a factor and additionally, more markets encounter difficulties led by Mobility which suffers from a serious slowdown in the UK and Australia. Also, Places weakens. Resilience is doing better but not strong enough to compensate for the other GBAs. We fine-tune our estimates, expecting virtually no organic growth and no margin improve...
Last Friday Fugro reported it has secured four Petrobras contracts for subsea inspection and monitoring in Brazil, valued at approximately $340m over four years starting in 4Q25 with optional one-year extensions. Three contracts are renewals under improved terms, while one is new and incremental. All were already included in Fugro's 12-month backlog as of March 2025. Each contract is vessel-specific, with two operated by Fugro and two by partners, all equipped with ROVs. The scope includes expan...
We downgrade Ontex from Buy to HOLD and cut our target price from €13.83 to €8.2 following a change in primary analyst. We expect 2025 to be another year of heavy restructuring, leading to peak capex which is required, in our view, to modernise its industrial footprint and enable it to compete profitably on larger contracts going forwards. We see this limiting Ontex's organic growth in the short term to 2.7% in FY25F, despite capex on sales of c.6%. Although €115m in divestment proceeds is expec...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.